MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer.
Adam J, Sourisseau T, Olaussen KA, Robin A, Zhu CQ, Templier A, Civet A, Girard P, Lazar V, Validire P, et al. Cancer Biomark. 2016 Sep 26; 17(3):323-333.